NL-OMON51902招募中不适用
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma - Atalanta-1
CellPoint B.V.0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Signed informed consent form
- •2. Age >= 18 years
- •3. Histologically confirmed diagnosis of one of the following non-Hodgkin
- •lymphoma subtypes: DLBCL, FL grade 1, 2 or 3A, MZL, or MCL
- •4. Relapsed or refractory disease
- •5. Measurable disease according to the Lugano classification
- •6. ECOG performance status of 0 or 1 (ECOG 2 is allowed when serum albumin >=
- •7. Adequate bone marrow, renal, hepatic and pulmonary function
排除标准
- •1. Primary CNS B-cell lymphoma, Burkitt lymphoma, or Richter*s transformation
- •2. Selected prior treatments as defined in the protocol
- •3. History of another primary malignancy that requires intervention beyond
- •surveillance or that has not been in remission for at least 3 years (exceptions
- •per protocol)
- •4. Active CNS involvement (with neurological changes) by disease under study
- •5. Infection with HIV, hepatitis B or hepatitis C virus
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphomaRelapsed/refractory B-cell non-Hodgkin lymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-003272-13-NLCellPoint B.V.45
进行中（未招募）
1 期
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphomaEUCTR2021-003272-13-BECellPoint B.V.45
进行中（未招募）
1 期
A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphomaCTIS2022-502661-23-00Galapagos40
进行中（未招募）
2 期
High powered ultrasound to treat pancreas cancerocally advanced pancreatic cancerMalignant neoplasm of pancreasCancerISRCTN56087634niversity of Oxford20
招募中
1 期
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)on-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-503920-14-00F. Hoffmann-La Roche AG385